









Markets
/
Stocks
/
nasdaq-casi
/

CASI Pharmaceuticals Inc

CASI

1.350USD

+0.020+1.50%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

20.92MMarket Cap

LossP/E TTM



CASI Pharmaceuticals Inc

1.350

+0.020+1.50%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CASI Pharmaceuticals Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CASI Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

81 / 159

Overall Ranking

230 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

4.000

Target Price

+187.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

CASI Pharmaceuticals Inc Highlights

StrengthsRisks

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Growing

The company is in a growing phase, with the latest annual income totaling USD 28.54M.

Overvalued

The company’s latest PE is -0.46, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.16M shares, decreasing 14.09% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 39.20K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 12.46.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 7.18, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 4.17M, representing a year-over-year increase of 4.93%, while its net profit experienced a year-over-year increase of 92.03%.

Score

Industry at a Glance

Previous score

7.18

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.30

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.54

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.05

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

CASI Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.80, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -0.46, which is -11.28% below the recent high of -0.41 and -745.12% above the recent low of -3.89.

Score

Industry at a Glance

Previous score

8.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 81/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for CASI Pharmaceuticals Inc is 4.00, with a high of 4.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

4.000

Target Price

+200.75%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

CASI Pharmaceuticals Inc

CASI

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.66, which is lower than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 1.87 and the support level at 1.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.65

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.060

Sell

RSI(14)

34.107

Neutral

STOCH(KDJ)(9,3,3)

8.960

Oversold

ATR(14)

0.153

High Vlolatility

CCI(14)

-106.899

Sell

Williams %R

91.524

Oversold

TRIX(12,20)

-1.010

Sell

StochRSI(14)

53.390

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.374

Sell

MA10

1.474

Sell

MA20

1.646

Sell

MA50

1.839

Sell

MA100

1.711

Sell

MA200

1.927

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 20.42%, representing a quarter-over-quarter decrease of 71.65%. The largest institutional shareholder is James Simons, holding a total of 39.20K shares, representing 0.25% of shares outstanding, with 0.51% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Panacea Venture Healthcare Fund I LP

3.55M

+73.17%

He (Wei-Wu)

3.52M

+11.33%

Sparkle Byte Ltd

1.02M

VR Adviser, LLC

987.26K

IDG Capital Partners

915.85K

+7.26%

Wealth Strategy Holding Ltd

908.79K

Foresite Capital Management, LLC

787.12K

-40.79%

Woodline Partners LP

165.64K

+0.78%

Wellington Shields Capital Management, LLC

90.84K

-0.05%

Adar1 Capital Management LLC

44.12K

-6.96%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.36, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.82. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.